Multiple Myeloma, Version 2.2016
Kenneth Carl Anderson, Melissa Alsina, Djordje Atanackovic et al. · Journal of the National Comprehensive Cancer Network · 2015
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. Recent statistics from the American Cancer Society indicate that the incidence of MM is increasing. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) included in this issue address management of patients with solitary plasmacytoma and newly diagnosed MM.
Cited by 73 works. doi:10.6004/jnccn.2015.0167 Open-access PDF
Authors
- Kenneth Carl Anderson
- Melissa Alsina
- Djordje Atanackovic
- Janet Sybil Biermann
- Jason Claud Chandler
- Caitlin L. Costello
- Benjamin Djulbegović
- Henry C.H. Fung
- Cristina Gasparetto
- Kelly Nicole Godby
- Craig C. Hofmeister
- Leona Holmberg
- Sarah A. Holstein
- Carol Ann Huff
- Adetola A. Kassim
- Amrita Y. Krishnan
- Shaji Kunnathu Kumar
- Michaela Liedtke
- Matthew Alexander Lunning
- Noopur S Raje
References
- Cancer statistics, 2015
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
- A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
- A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA
- International uniform response criteria for multiple myeloma
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- International Staging System for Multiple Myeloma
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
- Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group